Hipra's mypravac suis vaccine is for the prevention of respiratory disease due to Mycoplasma hyopneumoniae. It protects from the first week of life to the end of grow-finishing. The vaccine presents a new combination of adjuvants based on levamisole and carbomer, offering higher and longer-lasting immunity while avoiding adverse reactions since it is non-oil based. Administration is also improved.
